[Source: npj Vaccines, full page: (LINK). Abstract, edited.]
Article | OPEN | Published: 25 January 2019
Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus
Fangfang Dong, Dandan Li, Dan Wen, Suhua Li, Chaoyue Zhao, Yue Qi, Rohit K. Jangra, Cuiping Wu, Dequan Xia, Xing Zhang, Fei Deng, Kartik Chandran, Zhen Zou, Fei Yuan & Aihua Zheng
npj Vaccines, volume 4, Article number: 5 (2019)
Severe fever with thrombocytopenia virus (SFTSV) is an emerging tick-borne phlebovirus that causes lethal human disease, for which there are no licensed antiviral vaccines or therapies. Herein, we developed a live attenuated recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins (rVSV-SFTSV/AH12-GP). High titers of cross-protective, broadly neutralizing antibodies were elicited by a single dose of rVSV-SFTSV/AH12-GP in both immunocompetent and immunocompromised mice against multiple strains of SFTSV and the related but distinct phlebovirus Heartland virus (HRTV). Remarkably, complete protection against lethal challenge with SFTSV was conferred in young and old immunocompromised mice irrespective of any pre-existing vector-specific immunity. Collectively, these results suggest that a rVSV vector expressing SFTSV glycoproteins is a promising candidate vaccine against two emerging phleboviruses associated with severe human diseases.
Keywords: Phlebovirus; SFTS virus; Vaccines; Animal models.